Skip to main navigation
Skip to search
Skip to main content
University of Edinburgh Research Explorer Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Datasets
Prizes
Activities
Press/Media
Equipment
Search by expertise, name or affiliation
Targeting persister cell states that drive drug resistance and metastasis
Patton, Elizabeth
(Principal Investigator)
Deanery of Molecular, Genetic and Population Health Sciences
Overview
Fingerprint
Research output
(2)
Project Details
Status
Finished
Effective start/end date
1/10/20
→
30/09/23
Funding
Non-EU-based charities:
£98,213.00
View all
View less
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Zebra Fish
Pharmacology, Toxicology and Pharmaceutical Science
100%
Pharmacotherapy
Pharmacology, Toxicology and Pharmaceutical Science
100%
Drug Resistance
Pharmacology, Toxicology and Pharmaceutical Science
100%
Melanoma
Pharmacology, Toxicology and Pharmaceutical Science
100%
Melanocyte
Immunology and Microbiology
100%
Stem Cell
Immunology and Microbiology
100%
Lineages
Immunology and Microbiology
100%
Drug Formulation
Pharmacology, Toxicology and Pharmaceutical Science
12%
Research output
Research output per year
2022
2022
2022
2
Article
Research output per year
Research output per year
Aldh2 is a lineage-specific metabolic gatekeeper in melanocyte stem cells
Brunsdon, H.
,
Brombin, A.
, Peterson, S., Postlethwait, J. H. &
Patton, E. E.
,
29 Apr 2022
, (E-pub ahead of print)
In:
Development.
Research output
:
Contribution to journal
›
Article
›
peer-review
Open Access
File
Lineages
100%
Stem Cell
100%
Melanocyte
100%
Zebra Fish
12%
Cell Function
12%
Long-term non-invasive drug treatments in adult zebrafish that lead to melanoma drug resistance
Lu, Y. &
Patton, E. E.
,
8 Apr 2022
, (E-pub ahead of print)
In:
Disease Models and Mechanisms.
Research output
:
Contribution to journal
›
Article
›
peer-review
Open Access
File
Zebra Fish
100%
Pharmacotherapy
100%
Drug Resistance
100%
Melanoma
100%
Drug Discovery
12%